Search results for "Anemia"

showing 10 items of 352 documents

Red blood cell distribution width is not related with inflammatory parameters in morbidly obese patients

2013

Red blood cell distribution width (RDW) is a hematological parameter that has been studied in several clinical settings and has been found to be related to both anemia and inflammatory status. As obesity is related to increased inflammatory pattern, we aimed to analyze the RDW in this setting.We determined hematological and inflammatory parameters in morbidly obese patients before bariatric surgery (n=142) and normo-weight controls (n=144).RDW was higher in patients than in controls (p0.001), along with C-reactive protein (p0.001) and fibrinogen, (p0.001) while hemoglobin (p=0.026), serum iron (p0.001), MCH (p=0.002) and MCHC (p0.001) were lower in morbidly obese patients. The logistic corr…

AdultErythrocyte IndicesMalemedicine.medical_specialtyAnemiaClinical BiochemistryInflammationMorbidly obeseGastroenterologyInternal medicinemedicineHumansInflammationErythrocyte indicesbusiness.industryRed blood cell distribution widthGeneral Medicinemedicine.diseaseObesityObesity MorbidRed blood cellmedicine.anatomical_structureCase-Control StudiesHypochromiaImmunologyFemalemedicine.symptombusinessClinical Biochemistry
researchProduct

Detection of iron restriction in anaemic and non-anaemic patients: New diagnostic approaches.

2017

Objective The aim of this study was to detect iron restriction in non-anaemic patients and iron-restricted erythropoiesis (IRE) in patients with anaemia. Method Haematologic indices and biochemical markers of iron deficiency (ID) were determined using the clinically accepted cut-off level for serum ferritin of ≤30 μg/l as reference of ID. To evaluate the prevalence of iron restriction and IRE in patients with higher ferritin levels we used the thresholds of the markers of ID as reference. Results In the anaemic group 17.1% of patients with ferritin levels >30 μg/l had IRE. The number of patients with IRE declined with increasing ferritin concentration. Approximately 14% of patients without …

AdultErythrocyte IndicesMalemedicine.medical_specialtyAnemiaIron030204 cardiovascular system & hematologyGastroenterologySingle test03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineReceptors TransferrinmedicineHumansIn patientErythropoiesis030212 general & internal medicineSoluble transferrin receptorAgedAged 80 and overbiologyAnemia Iron-DeficiencyRED-CELL INDICESfungiAnemiaHematologyGeneral MedicineIron deficiencyMiddle Agedmedicine.diseaseFerritinROC CurveImmunologyFerritinsbiology.proteinErythropoiesisFemaleBiomarkersEuropean journal of haematology
researchProduct

Protein�A immunoadsorption therapy for refractory, mitomycin�C?associated thrombotic microangiopathy

2007

BACKGROUND: Mitomycin C–associated thrombotic microangiopathy (TMA) has a poor prognosis with limited therapeutic options. Most patients die within 4 months of diagnosis due to pulmonary or renal failure. Here, a patient resistant to total plasma exchange (TPE) and immunosuppressive therapy with glucocorticoids, rituximab, vincristine, and splenectomy who was successfully treated with protein A immunoadsorption is described. CASE REPORT: A 29-year-old woman developed a TMA after chemotherapy with mitomycin C. She presented with thrombocytopenia, pulmonary edema, hemolytic anemia with presence of schistocytes, and renal failure. Immediate TPE (>120 times) and immunosuppressive therapy with g…

AdultHemolytic anemiamedicine.medical_specialtyThrombotic microangiopathyMitomycinmedicine.medical_treatmentImmunologySplenectomyGastroenterologyInternal medicinemedicineHumansImmunology and AllergyStaphylococcal Protein AImmunoadsorptionImmunosorbent TechniquesSalvage TherapyChemotherapyPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionHematologymedicine.diseaseSurgerySchistocyteTreatment OutcomeHemolytic-Uremic SyndromeFemaleRituximabbusinessmedicine.drugTransfusion
researchProduct

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

2021

Abstract Introduction With the increasing use of checkpoint inhibitors, rare immune-related adverse events (irAE) are being identified. Haematological irAE (hem-irAE) are difficult to treat and have shown high mortality rates. In order to improve side-effect management for these potentially life-threatening events, we analysed frequency, severity and outcomes. Patients and methods Patients who developed hem-irAE while being treated with immune checkpoint inhibitors (ICI) therapy were retrospectively identified from 18 international cancer centres. Results In total, more than 7626 patients treated with ICI were screened, and 50 patients with hem-irAE identified. The calculated incidence amou…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyNeutropeniamedicine.medical_treatmentMedizinNeutropeniamedicine.disease_causeGastroenterologyAutoimmunityYoung Adult03 medical and health sciences0302 clinical medicineImmune systemAdrenal Cortex HormonesInternal medicinemedicineHumansAdverse effectImmune Checkpoint InhibitorsAgedRetrospective StudiesAged 80 and overHemophagocytic lymphohistiocytosisbusiness.industryIncidenceIncidence (epidemiology)CancerAnemiaImmunosuppressionMiddle Agedmedicine.diseaseThrombocytopeniaTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemalebusinessImmunosuppressive Agents
researchProduct

Fever of Unclear Origin and Cytopenia Because of Acute Splenic Sequestration in a Young Immunocompetent Carrier of Beta-Globin Mutation for Hb Vallet…

2008

Fever of unclear origin is a clinical challenge in medical practice. Infectious diseases, neoplasms, and collagen vascular illnesses are its main causes in adults and children. Acute splenic sequestration crises, a known potentially fatal complication of sickle cell disease and sickle beta-thalassemia, are uncommon in beta-heterozygosis. We describe a case of prolonged recurrent episodes of fever with spontaneous resolution, commencing at age 10 in a 15-year-old boy with a history of hypochromic microcytic anemia attributed to a thalassemic trait. He was admitted twice to our university hospital for continuous-remittent fever with a pruritic, macular evanescent Still's skin rash, severe spl…

AdultMaleAdolescentFeverAnemiaHemoglobins AbnormalThalassemiaHepatosplenomegalybeta-Globinshemic and lymphatic diseasesmedicineHumansChildCytopeniabusiness.industryBeta thalassemiaAnemiaGeneral Medicinemedicine.diseaseHematologic DiseasesHypochromic microcytic anemiaHemoglobinopathyMutationImmunologymedicine.symptomSplenic diseasebusinessImmunocompetenceSpleenThe American Journal of the Medical Sciences
researchProduct

Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.

2015

Phenotypic improvement of hemoglobinopathies such as sickle cell disease and β-thalassemia (β-thal) has been shown in patients with high levels of Hb F. Among the drugs proposed to increase Hb F production, hydroxyurea (HU) is currently the only one proven to improve the clinical course of these diseases. However, Hb F increase and patient's response are highly variable, indicating that new pharmacological agents could be useful for patients not responding to HU or showing a reduction of response during long-term therapy. In this study we evaluated the efficacy of rapamycin, a lypophilic macrolide used for the prevention of acute rejection in renal transplant recipients, as an inducer of Hb…

AdultMaleAdolescentGenotypeThalassemiaClinical BiochemistryCellDiseaseAnemia Sickle Cellbeta-GlobinsPharmacologyBiologyYoung Adultalpha-GlobinsIn vivomedicineHumansHydroxyureaInducergamma-GlobinsGenetics (clinical)Cells CulturedFetal HemoglobinAgedErythroid Precursor CellsSirolimusBiochemistry (medical)beta-ThalassemiaClinical courseHematologyMiddle Agedmedicine.diseasePhenotypeMolecular biologyIn vitromedicine.anatomical_structureGene Expression RegulationMutationFemaleHemoglobin
researchProduct

Prediction of the hemoglobin level in hemodialysis patients using machine learning techniques

2013

HighlightsDifferent prediction algorithms were used to predict Hb levels in CRF patients.Prediction errors in the validation cohorts of patients were around 0.6g/dl.Difficulty to obtain lower errors due to the measuring machine precision (0.2g/dl).Relevance analysis of features have been applied for each predictor. Patients who suffer from chronic renal failure (CRF) tend to suffer from an associated anemia as well. Therefore, it is essential to know the hemoglobin (Hb) levels in these patients. The aim of this paper is to predict the hemoglobin (Hb) value using a database of European hemodialysis patients provided by Fresenius Medical Care (FMC) for improving the treatment of this kind of …

AdultMaleAdolescentmedicine.medical_treatmentHealth InformaticsMachine learningcomputer.software_genreDisease clusterSensitivity and SpecificityHemoglobinsYoung AdultArtificial IntelligenceRenal DialysismedicineHumansComputer SimulationCluster analysisErythropoietinAgedAged 80 and overDose-Response Relationship DrugArtificial neural networkbusiness.industryModels CardiovascularLinear modelReproducibility of ResultsAnemiaMiddle AgedRegressionDrug Therapy Computer-AssistedComputer Science ApplicationsSupport vector machineTreatment OutcomeAdaptive resonance theoryFemaleHemodialysisArtificial intelligenceDrug MonitoringbusinesscomputerAlgorithmsBiomarkersSoftwareComputer Methods and Programs in Biomedicine
researchProduct

Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: A phase II trial

2005

A number of second line treatments have been proposed in patients with advanced pretreated non-small cell lung cancer (NSCLC). However, either single agents or two or three drug combinations achieved very poor results with no superiority of any combination over monotherapy. We have treated 42 patients (30 males) affected by advanced/metastatic NSCLC progressing during front line cisplatin-based chemotherapy with a combination of topotecan (1.2 mg/m2) plus ifosfamide (1200 mg/m2) for 3 consecutive days every 3 weeks. The median age was 63 years (range 43-76); cell types were: squamous carcinoma (n=17), adenocarcinoma (n=16), large cell carcinoma (n=3), broncho-alveolar carcinoma (n=2) and un…

AdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniamedicine.medical_treatmentGastroenterologychemistry.chemical_compoundCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIfosfamideInfusions IntravenousLung cancerSurvival rateAgedPlatinumChemotherapyIfosfamidebusiness.industryAlopeciaAnemiaGeneral MedicineMiddle Agedmedicine.diseaseThrombocytopeniaCarboplatinSquamous carcinomaSurgeryOxaliplatinTreatment OutcomeOncologychemistryDrug Resistance NeoplasmFemaleTopotecanTopotecanbusinessmedicine.drug
researchProduct

Splenic marginal zone lymphoma with or without villous lymphocytes

2004

BACKGROUND Splenic marginal zone lymphoma (SMZL) is a well defined pathologic entity. However, questions regarding the bone marrow infiltration rate, the minimal diagnostic data set, and therapy remain unanswered. METHODS Clinical-pathologic features and outcomes of 57 consecutive patients who had splenomegaly with no clinically significant lymphadenomegaly and who were diagnosed with SMZL with or without (±) villous lymphocytes (VL) were reviewed. RESULTS SMVL ± VL occurred mostly in elderly males (median age, 62 years ± 10 years; male-to-female ratio, (1.85). Anemia was recorded in 49% of patients, and 30% of patients had moderate thrombocytopenia. Leukocytosis and leukopenia were found i…

AdultMaleCancer Researchmedicine.medical_specialtyLymphomaAnemiamedicine.medical_treatmentSplenectomysplenic marginal zone lymphomaGastroenterologyBone marrow biopsyIntrasinusoidalInternal medicinemedicineHumansLymphocytesLeukocytosisSplenic marginal zone lymphomaSurvival rateAgedAged 80 and overLeukopeniabusiness.industrySplenic Neoplasmssplenic marginal zone lymphoma; PrognosisSplenic lymphoma with villous lymphocytesMiddle AgedPrognosismedicine.diseaseSplenic NeoplasmSurgerySurvival Ratemedicine.anatomical_structureOncologySplenectomySplenic lymphoma with villous lymphocyteLymphocyteFemaleBone marrowmedicine.symptombusinessHumanCancer
researchProduct

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 + T Cells To Predict CMV DNAemia Clearance in …

2014

ABSTRACT It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8 + T cells) appeared to perform better for this purpose.

AdultMaleGanciclovirvirusesCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesClinical TherapeuticsViral Matrix ProteinsInterferon-gammamedicineHumansValganciclovirCytotoxic T cellPharmacology (medical)GanciclovirMultiple myelomaPharmacologybusiness.industryLymphoma Non-HodgkinAnemia Aplasticvirus diseasesValganciclovirMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPhosphoproteinsmedicine.diseaseTransplant RecipientsLeukemia Myeloid AcuteLeukemiaInfectious DiseasesCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellMultiple MyelomabusinessCD8Stem Cell Transplantationmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct